Booth #637 

Orange County Convention Center,  Orlando, FL.

Meet us and discover how the GARD^® assays are transforming skin sensitization testing. Learn about their role in filling data gaps for in vitro skin sensitizing hazard and quantitative potency assessment, providing a high-performing and ethical alternative to animal testing.

Exhibitor-Hosted Session

Advancing NAMs for Skin Sensitization Testing: Potency, Challenging Substances and Medical Devices

W208B | Tuesday, 18 Mar | 10:45 am-11:45 am

Bring your questions and testing challenges!

Join us for an interactive session that combines essential regulatory updates, case studies, and a live Q&A! Gain exclusive insights on the latest GARD^®data from SenzaGen’s research and industry collaborations, including key advancements in testing challenging substances, medical devices, and quantitative potency assessment. We will also share user cases from industry leaders like dōTERRA, Clarins, and Bic Skin Creative.

Our experts will be available to discuss how GARD^® innovations can address your needs and advance your work in skin sensitization testing.

Key Topics

• New GARD^® data from industry collaborations on Natural Extracts and Quantitative Potency Assessment.
• Regulatory update WG8 ISO TC194: Medical Devices ISO 10993-10.
• User Cases from dōTERRA, Clarins, Bic Skin Creative, and more.

Speakers

• Ron Brown, Toxicologist at Risk Science Consortium (former FDA reviewer for Medical Devices)
• Joe Dawson, Product Safety Manager at doTERRA International
• Andy Forreryd, Scientific Liaison, SenzaGen

Posters

🎫 G367 | Skin Sensitization Potency GHS/CLP Classification

March 17, 1:45 pm -4:15 pm | #3242 Subcategorization of skin sensitizers into UN GHS categories using GARD^®skin Dose-Response

🎫 D217 | Medical Devices Testing ISO 10993-10

March 19, 9:15 am -11:45 am | #4382 Pre-validation Results from GARD^®skin for Medical Devices: In Vitro Sensitization Testing of Medical Device Extracts for Implementation in ISO 10993-10

🎫 LB352 | NAMs in Occupational Health – Joint poster with Lundbeck

March 20, 8:30 am -11:30 am | #5251 Assessing skin sensitizing hazard of Drug Products and Active Pharmaceutical Ingredients using GARD^®: New Approach Methodology in Occupational Health and Safety

🎫 F310 |  Application for Pharmaceuticals – Joint poster presented by SafeBridge

Mar 18, 1:45 pm-4 pm | #3838 Comparison of β-lactam ring containing substances gene expression signatures related to therapeutic mechanism and the Adverse Outcome Pathway (AOP) for sensitization